- Home
- NEO vs HCM Comparison
NEO vs HCM Comparison
Compare NEO & HCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NEO
- HCM
- Stock Information
- Founded
- NEO 2001
- HCM 2000
- Country
- NEO United States
- HCM Hong Kong
- Employees
- NEO N/A
- HCM N/A
- Industry
- NEO Precision Instruments
- HCM Biotechnology: Pharmaceutical Preparations
- Sector
- NEO Health Care
- HCM Health Care
- Exchange
- NEO Nasdaq
- HCM Nasdaq
- Market Cap
- NEO 2.3B
- HCM 2.6B
- IPO Year
- NEO 1999
- HCM N/A
- Fundamental
- Price
- NEO $14.18
- HCM $14.21
- Analyst Decision
- NEO Strong Buy
- HCM Hold
- Analyst Count
- NEO 10
- HCM 1
- Target Price
- NEO $20.56
- HCM $19.00
- AVG Volume (30 Days)
- NEO 1.2M
- HCM 73.7K
- Earning Date
- NEO 02-18-2025
- HCM 02-26-2025
- Dividend Yield
- NEO N/A
- HCM N/A
- EPS Growth
- NEO N/A
- HCM N/A
- EPS
- NEO N/A
- HCM N/A
- Revenue
- NEO $644,118,000.00
- HCM $610,806,000.00
- Revenue This Year
- NEO $12.98
- HCM N/A
- Revenue Next Year
- NEO $9.94
- HCM $20.69
- P/E Ratio
- NEO N/A
- HCM N/A
- Revenue Growth
- NEO 12.06
- HCM N/A
- 52 Week Low
- NEO $12.13
- HCM $11.93
- 52 Week High
- NEO $19.11
- HCM $21.92
- Technical
- Relative Strength Index (RSI)
- NEO 40.28
- HCM 42.42
- Support Level
- NEO $13.93
- HCM $13.00
- Resistance Level
- NEO $16.18
- HCM $14.32
- Average True Range (ATR)
- NEO 1.13
- HCM 0.47
- MACD
- NEO -0.33
- HCM 0.01
- Stochastic Oscillator
- NEO 29.37
- HCM 38.05
About NEO NeoGenomics Inc.
NeoGenomics Inc operates a network of cancer-focused genetic testing laboratories in the United States as well as a laboratory in Switzerland. The company operates into two segments namely Clinical Services and Advanced Diagnostics. It offers types of genetic and molecular testing services namely Cytogenetics, Fluorescence In-Situ Hybridization, Flow cytometry, Immunohistochemistry, Molecular testing, Pathology consultation. Advanced Diagnostics segment supports pharmaceutical firms in their drug development programs by supporting various clinical trials and research. For Clinical Services, Its specialized diagnostic services are performed based on an online test order or a written test requisition form. The company generates majority of its revenue from Clinical Services.
About HCM HUTCHMED (China) Limited
HUTCHMED (China) Ltd is an innovative biopharmaceutical company engaged in the discovery, global development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures.